Addition of sildenafil in patients with pulmonary arterial hypertension with inadequate response to bosentan monotherapy

Canadian Respiratory Journal

Volumn 15, Issue 8, 2008, Pages 427-430

  Porhownik, Nancy R ^a,b   Al Sharif, Hassan ^a   Bshouty, Zoheir ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

^b Section of Respiratory Medicine   (Canada)

Author keywords

Bosentan; Combination therapy; Pulmonary arterial hypertension; Sildenafil

Indexed keywords

BOSENTAN; SILDENAFIL; ANTIHYPERTENSIVE AGENT; PHOSPHODIESTERASE INHIBITOR; PIPERAZINE DERIVATIVE; PURINE DERIVATIVE; SULFONAMIDE; SULFONE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE CLASSIFICATION; DRUG RESPONSE; EXERCISE TOLERANCE; FEMALE; HUMAN; MALE; MONOTHERAPY; PRIORITY JOURNAL; PULMONARY HYPERTENSION; TREATMENT DURATION; WALKING; DRUG COMBINATION; MIDDLE AGED; TREATMENT FAILURE;

ADULT; AGED; ANTIHYPERTENSIVE AGENTS; DRUG THERAPY, COMBINATION; EXERCISE TOLERANCE; FEMALE; HUMANS; HYPERTENSION, PULMONARY; MALE; MIDDLE AGED; PHOSPHODIESTERASE INHIBITORS; PIPERAZINES; PURINES; SULFONAMIDES; SULFONES; TREATMENT FAILURE; YOUNG ADULT;

EID: 60749109050     PISSN: 11982241     EISSN: None     Source Type: Journal    
DOI: 10.1155/2008/897102     Document Type: Article

References (9)

1. Hoeper MM, Markevych I, Spiekerkoetter E, Welte T, Niedermeyer J. Goal-oriented treatment and combination therapy for pulmonary arterial hypertension. Eur Respir J 2005;26:858-63.
2. Burgess G, Hoogkamer H, Collings L, Dingemanse J. Mutual pharmacokinetic interactions between steady-state bosentan and sildenafil. Eur J Clin Pharmacol 2008;64:43-50.
3. Sitbon O, Humbert M, Nunes H, et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: Prognostic factors and survival. J Am Coll Cardiol 2002;347:322-9.
4. D'Alonzo GE, Barst RJ, Ayres SM, et al. Survival in patients with primary pulmonary hypertension. Ann Intern Med 1991;115:343-9.
5. O'Callaghan D, Gaine SP. Combination therapy and new types of agents for pulmonary arterial hypertension. Clin Chest Med 2007;28:169-85.
6. ATS statement: Guidelines for the six-minute walk test. Am J Respir Crit Care Med 2002;166:111-7.
7. The Criteria Committee of the New York Heart Association. Nomenclature and Criteria for Diagnosis of Diseases of the Heart and Great Vessels, 9th edn. Boston: Little, Brown, & Co, 1994:253-6.
8. Hoeper MM, Faulenbach C, Golpon H, et al. Combination therapy with bosentan and sildenafil in idiopathic pulmonary arterial hypertension. Eur Respir J 2004:24:1007-10.
9. Mathai SC, Girgis RE, Fisher MR, et al. Addition of sildenafil to bosentan monotherapy in pulmonary arterial hypertension. Eur Respir J 2007;29:469-75.